Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

Hartwig P. Huemer, Birgit Strobl, Norbert Nowotny

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

Original languageEnglish
Pages (from-to)1320-1326
Number of pages7
JournalVaccine
Volume18
Issue number14
DOIs
Publication statusPublished - Feb 4 2000

Fingerprint

Equid Herpesvirus 1
Equid herpesvirus 1
Vaccinia virus
recombinant DNA
Recombinant DNA
plasmids
Vaccination
Plasmids
vaccination
vaccines
antigens
Combined Vaccines
Antigens
Complement Receptors
DNA
Humoral Immunity
hamsters
application methods
humoral immunity
Cellular Immunity

Keywords

  • DNA vaccine
  • EHV
  • MVA
  • Vaccinia virus

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme. / Huemer, Hartwig P.; Strobl, Birgit; Nowotny, Norbert.

In: Vaccine, Vol. 18, No. 14, 04.02.2000, p. 1320-1326.

Research output: Contribution to journalArticle

@article{444499cf5d1643568778f340b1ba0185,
title = "Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme",
abstract = "The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.",
keywords = "DNA vaccine, EHV, MVA, Vaccinia virus",
author = "Huemer, {Hartwig P.} and Birgit Strobl and Norbert Nowotny",
year = "2000",
month = "2",
day = "4",
doi = "10.1016/S0264-410X(99)00413-2",
language = "English",
volume = "18",
pages = "1320--1326",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "14",

}

TY - JOUR

T1 - Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

AU - Huemer, Hartwig P.

AU - Strobl, Birgit

AU - Nowotny, Norbert

PY - 2000/2/4

Y1 - 2000/2/4

N2 - The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

AB - The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

KW - DNA vaccine

KW - EHV

KW - MVA

KW - Vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=0033957536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033957536&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00413-2

DO - 10.1016/S0264-410X(99)00413-2

M3 - Article

C2 - 10618528

AN - SCOPUS:0033957536

VL - 18

SP - 1320

EP - 1326

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 14

ER -